StephenJNogaMDPh.D.

Hematologic Oncology

Medical Oncologist

Dr. Noga is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1990 - 1992
Johns Hopkins UniversityResidency, Internal Medicine, 1987 - 1990
Johns Hopkins University School of MedicineClass of 1987

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012

PubMed

2 citations
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati
Blood Cancer Journal. 2023-09-19
10 citations
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak
Clinical Lymphoma, Myeloma & Leukemia. 2020-11-01
2 citations
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup ...
Cindy Weinstein, Karin Jordan, Stuart A. Green, S. Khanani, Elizabeth Beckford-Brathwaite
BMC Cancer. 2020-09-25

Abstracts/Posters

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Stephen J Noga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Isct 9th Annual Meeting: Isct 2003National Cancer Institute2003
Core--Hematopoietic And Therapeutic Support FacilityNational Cancer Institute2001–2002
Core--Hematopoietic &Therapeutic Support ServiceNational Cancer Institute2001–2002
Core--Graft Engineering LaboratoryNational Cancer Institute1996–2000
Core--Graft Engineering FacilityNational Cancer Institute1996–2000
Engineering Alternative Donor Grafts To Improve SurvivalNational Cancer Institute1995–1998